

Global Acute Migraine Drugs Market Growth 2024-2030

<https://marketpublishers.com/r/GA4B2935FD7EN.html>

Date: January 2024

Pages: 91

Price: US\$ 3,660.00 (Single User License)

ID: GA4B2935FD7EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Acute Migraine Drugs market size was valued at US\$ 2058.6 million in 2023. With growing demand in downstream market, the Acute Migraine Drugs is forecast to a readjusted size of US\$ 3431.6 million by 2030 with a CAGR of 7.6% during review period.

The research report highlights the growth potential of the global Acute Migraine Drugs market. Acute Migraine Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Acute Migraine Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Acute Migraine Drugs market.

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient's quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.

The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.

Key Features:

The report on Acute Migraine Drugs market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Acute Migraine Drugs market. It may include historical data, market segmentation by Type (e.g., Triptans, NSAIDs), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Acute Migraine Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Acute Migraine Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Acute Migraine Drugs industry. This include advancements in Acute Migraine Drugs technology, Acute Migraine Drugs new entrants, Acute Migraine Drugs new investment, and other innovations that are shaping the future of Acute Migraine Drugs.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Acute Migraine Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Acute Migraine Drugs product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Acute Migraine Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Acute Migraine Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Acute Migraine Drugs market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Acute Migraine Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Acute Migraine Drugs market.

Market Segmentation:

Acute Migraine Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Triptans

NSAIDs

Others

Segmentation by application

Hospital Pharmacies

Drug Stores

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

GSK

Teva

Pfizer

Novartis

Sun Pharma

Grunenthal

Endo Pharmaceuticals

Merck

J & J

Key Questions Addressed in this Report

What is the 10-year outlook for the global Acute Migraine Drugs market?

What factors are driving Acute Migraine Drugs market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Acute Migraine Drugs market opportunities vary by end market size?

How does Acute Migraine Drugs break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Acute Migraine Drugs Annual Sales 2019-2030
 - 2.1.2 World Current & Future Analysis for Acute Migraine Drugs by Geographic Region, 2019, 2023 & 2030
 - 2.1.3 World Current & Future Analysis for Acute Migraine Drugs by Country/Region, 2019, 2023 & 2030
- 2.2 Acute Migraine Drugs Segment by Type
 - 2.2.1 Triptans
 - 2.2.2 NSAIDs
 - 2.2.3 Others
- 2.3 Acute Migraine Drugs Sales by Type
 - 2.3.1 Global Acute Migraine Drugs Sales Market Share by Type (2019-2024)
 - 2.3.2 Global Acute Migraine Drugs Revenue and Market Share by Type (2019-2024)
 - 2.3.3 Global Acute Migraine Drugs Sale Price by Type (2019-2024)
- 2.4 Acute Migraine Drugs Segment by Application
 - 2.4.1 Hospital Pharmacies
 - 2.4.2 Drug Stores
- 2.5 Acute Migraine Drugs Sales by Application
 - 2.5.1 Global Acute Migraine Drugs Sale Market Share by Application (2019-2024)
 - 2.5.2 Global Acute Migraine Drugs Revenue and Market Share by Application (2019-2024)
 - 2.5.3 Global Acute Migraine Drugs Sale Price by Application (2019-2024)

3 GLOBAL ACUTE MIGRAINE DRUGS BY COMPANY

- 3.1 Global Acute Migraine Drugs Breakdown Data by Company
 - 3.1.1 Global Acute Migraine Drugs Annual Sales by Company (2019-2024)
 - 3.1.2 Global Acute Migraine Drugs Sales Market Share by Company (2019-2024)
- 3.2 Global Acute Migraine Drugs Annual Revenue by Company (2019-2024)
 - 3.2.1 Global Acute Migraine Drugs Revenue by Company (2019-2024)
 - 3.2.2 Global Acute Migraine Drugs Revenue Market Share by Company (2019-2024)
- 3.3 Global Acute Migraine Drugs Sale Price by Company
- 3.4 Key Manufacturers Acute Migraine Drugs Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Acute Migraine Drugs Product Location Distribution
 - 3.4.2 Players Acute Migraine Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR ACUTE MIGRAINE DRUGS BY GEOGRAPHIC REGION

- 4.1 World Historic Acute Migraine Drugs Market Size by Geographic Region (2019-2024)
 - 4.1.1 Global Acute Migraine Drugs Annual Sales by Geographic Region (2019-2024)
 - 4.1.2 Global Acute Migraine Drugs Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Acute Migraine Drugs Market Size by Country/Region (2019-2024)
 - 4.2.1 Global Acute Migraine Drugs Annual Sales by Country/Region (2019-2024)
 - 4.2.2 Global Acute Migraine Drugs Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Acute Migraine Drugs Sales Growth
- 4.4 APAC Acute Migraine Drugs Sales Growth
- 4.5 Europe Acute Migraine Drugs Sales Growth
- 4.6 Middle East & Africa Acute Migraine Drugs Sales Growth

5 AMERICAS

- 5.1 Americas Acute Migraine Drugs Sales by Country
 - 5.1.1 Americas Acute Migraine Drugs Sales by Country (2019-2024)
 - 5.1.2 Americas Acute Migraine Drugs Revenue by Country (2019-2024)

- 5.2 Americas Acute Migraine Drugs Sales by Type
- 5.3 Americas Acute Migraine Drugs Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Acute Migraine Drugs Sales by Region
 - 6.1.1 APAC Acute Migraine Drugs Sales by Region (2019-2024)
 - 6.1.2 APAC Acute Migraine Drugs Revenue by Region (2019-2024)
- 6.2 APAC Acute Migraine Drugs Sales by Type
- 6.3 APAC Acute Migraine Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Acute Migraine Drugs by Country
 - 7.1.1 Europe Acute Migraine Drugs Sales by Country (2019-2024)
 - 7.1.2 Europe Acute Migraine Drugs Revenue by Country (2019-2024)
- 7.2 Europe Acute Migraine Drugs Sales by Type
- 7.3 Europe Acute Migraine Drugs Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Acute Migraine Drugs by Country
 - 8.1.1 Middle East & Africa Acute Migraine Drugs Sales by Country (2019-2024)

- 8.1.2 Middle East & Africa Acute Migraine Drugs Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Acute Migraine Drugs Sales by Type
- 8.3 Middle East & Africa Acute Migraine Drugs Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Acute Migraine Drugs
- 10.3 Manufacturing Process Analysis of Acute Migraine Drugs
- 10.4 Industry Chain Structure of Acute Migraine Drugs

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Acute Migraine Drugs Distributors
- 11.3 Acute Migraine Drugs Customer

12 WORLD FORECAST REVIEW FOR ACUTE MIGRAINE DRUGS BY GEOGRAPHIC REGION

- 12.1 Global Acute Migraine Drugs Market Size Forecast by Region
 - 12.1.1 Global Acute Migraine Drugs Forecast by Region (2025-2030)
 - 12.1.2 Global Acute Migraine Drugs Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country

- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Acute Migraine Drugs Forecast by Type
- 12.7 Global Acute Migraine Drugs Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 GSK

- 13.1.1 GSK Company Information
- 13.1.2 GSK Acute Migraine Drugs Product Portfolios and Specifications
- 13.1.3 GSK Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.1.4 GSK Main Business Overview
- 13.1.5 GSK Latest Developments

13.2 Teva

- 13.2.1 Teva Company Information
- 13.2.2 Teva Acute Migraine Drugs Product Portfolios and Specifications
- 13.2.3 Teva Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.2.4 Teva Main Business Overview
- 13.2.5 Teva Latest Developments

13.3 Pfizer

- 13.3.1 Pfizer Company Information
- 13.3.2 Pfizer Acute Migraine Drugs Product Portfolios and Specifications
- 13.3.3 Pfizer Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.3.4 Pfizer Main Business Overview
- 13.3.5 Pfizer Latest Developments

13.4 Novartis

- 13.4.1 Novartis Company Information
- 13.4.2 Novartis Acute Migraine Drugs Product Portfolios and Specifications
- 13.4.3 Novartis Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.4.4 Novartis Main Business Overview
- 13.4.5 Novartis Latest Developments

13.5 Sun Pharma

- 13.5.1 Sun Pharma Company Information
- 13.5.2 Sun Pharma Acute Migraine Drugs Product Portfolios and Specifications
- 13.5.3 Sun Pharma Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2019-2024)

13.5.4 Sun Pharma Main Business Overview

13.5.5 Sun Pharma Latest Developments

13.6 Grunenthal

13.6.1 Grunenthal Company Information

13.6.2 Grunenthal Acute Migraine Drugs Product Portfolios and Specifications

13.6.3 Grunenthal Acute Migraine Drugs Sales, Revenue, Price and Gross Margin
(2019-2024)

13.6.4 Grunenthal Main Business Overview

13.6.5 Grunenthal Latest Developments

13.7 Endo Pharmaceuticals

13.7.1 Endo Pharmaceuticals Company Information

13.7.2 Endo Pharmaceuticals Acute Migraine Drugs Product Portfolios and
Specifications

13.7.3 Endo Pharmaceuticals Acute Migraine Drugs Sales, Revenue, Price and Gross
Margin (2019-2024)

13.7.4 Endo Pharmaceuticals Main Business Overview

13.7.5 Endo Pharmaceuticals Latest Developments

13.8 Merck

13.8.1 Merck Company Information

13.8.2 Merck Acute Migraine Drugs Product Portfolios and Specifications

13.8.3 Merck Acute Migraine Drugs Sales, Revenue, Price and Gross Margin
(2019-2024)

13.8.4 Merck Main Business Overview

13.8.5 Merck Latest Developments

13.9 J & J

13.9.1 J & J Company Information

13.9.2 J & J Acute Migraine Drugs Product Portfolios and Specifications

13.9.3 J & J Acute Migraine Drugs Sales, Revenue, Price and Gross Margin
(2019-2024)

13.9.4 J & J Main Business Overview

13.9.5 J & J Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Acute Migraine Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Acute Migraine Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Triptans

Table 4. Major Players of NSAIDs

Table 5. Major Players of Others

Table 6. Global Acute Migraine Drugs Sales by Type (2019-2024) & (K Unit)

Table 7. Global Acute Migraine Drugs Sales Market Share by Type (2019-2024)

Table 8. Global Acute Migraine Drugs Revenue by Type (2019-2024) & (\$ million)

Table 9. Global Acute Migraine Drugs Revenue Market Share by Type (2019-2024)

Table 10. Global Acute Migraine Drugs Sale Price by Type (2019-2024) & (USD/Unit)

Table 11. Global Acute Migraine Drugs Sales by Application (2019-2024) & (K Unit)

Table 12. Global Acute Migraine Drugs Sales Market Share by Application (2019-2024)

Table 13. Global Acute Migraine Drugs Revenue by Application (2019-2024)

Table 14. Global Acute Migraine Drugs Revenue Market Share by Application (2019-2024)

Table 15. Global Acute Migraine Drugs Sale Price by Application (2019-2024) & (USD/Unit)

Table 16. Global Acute Migraine Drugs Sales by Company (2019-2024) & (K Unit)

Table 17. Global Acute Migraine Drugs Sales Market Share by Company (2019-2024)

Table 18. Global Acute Migraine Drugs Revenue by Company (2019-2024) (\$ Millions)

Table 19. Global Acute Migraine Drugs Revenue Market Share by Company (2019-2024)

Table 20. Global Acute Migraine Drugs Sale Price by Company (2019-2024) & (USD/Unit)

Table 21. Key Manufacturers Acute Migraine Drugs Producing Area Distribution and Sales Area

Table 22. Players Acute Migraine Drugs Products Offered

Table 23. Acute Migraine Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Acute Migraine Drugs Sales by Geographic Region (2019-2024) & (K Unit)

Table 27. Global Acute Migraine Drugs Sales Market Share Geographic Region (2019-2024)

Table 28. Global Acute Migraine Drugs Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 29. Global Acute Migraine Drugs Revenue Market Share by Geographic Region (2019-2024)

Table 30. Global Acute Migraine Drugs Sales by Country/Region (2019-2024) & (K Unit)

Table 31. Global Acute Migraine Drugs Sales Market Share by Country/Region (2019-2024)

Table 32. Global Acute Migraine Drugs Revenue by Country/Region (2019-2024) & (\$ millions)

Table 33. Global Acute Migraine Drugs Revenue Market Share by Country/Region (2019-2024)

Table 34. Americas Acute Migraine Drugs Sales by Country (2019-2024) & (K Unit)

Table 35. Americas Acute Migraine Drugs Sales Market Share by Country (2019-2024)

Table 36. Americas Acute Migraine Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 37. Americas Acute Migraine Drugs Revenue Market Share by Country (2019-2024)

Table 38. Americas Acute Migraine Drugs Sales by Type (2019-2024) & (K Unit)

Table 39. Americas Acute Migraine Drugs Sales by Application (2019-2024) & (K Unit)

Table 40. APAC Acute Migraine Drugs Sales by Region (2019-2024) & (K Unit)

Table 41. APAC Acute Migraine Drugs Sales Market Share by Region (2019-2024)

Table 42. APAC Acute Migraine Drugs Revenue by Region (2019-2024) & (\$ Millions)

Table 43. APAC Acute Migraine Drugs Revenue Market Share by Region (2019-2024)

Table 44. APAC Acute Migraine Drugs Sales by Type (2019-2024) & (K Unit)

Table 45. APAC Acute Migraine Drugs Sales by Application (2019-2024) & (K Unit)

Table 46. Europe Acute Migraine Drugs Sales by Country (2019-2024) & (K Unit)

Table 47. Europe Acute Migraine Drugs Sales Market Share by Country (2019-2024)

Table 48. Europe Acute Migraine Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 49. Europe Acute Migraine Drugs Revenue Market Share by Country (2019-2024)

Table 50. Europe Acute Migraine Drugs Sales by Type (2019-2024) & (K Unit)

Table 51. Europe Acute Migraine Drugs Sales by Application (2019-2024) & (K Unit)

Table 52. Middle East & Africa Acute Migraine Drugs Sales by Country (2019-2024) & (K Unit)

Table 53. Middle East & Africa Acute Migraine Drugs Sales Market Share by Country (2019-2024)

Table 54. Middle East & Africa Acute Migraine Drugs Revenue by Country (2019-2024) & (\$ Millions)

Table 55. Middle East & Africa Acute Migraine Drugs Revenue Market Share by Country (2019-2024)

Table 56. Middle East & Africa Acute Migraine Drugs Sales by Type (2019-2024) & (K Unit)

Table 57. Middle East & Africa Acute Migraine Drugs Sales by Application (2019-2024) & (K Unit)

Table 58. Key Market Drivers & Growth Opportunities of Acute Migraine Drugs

Table 59. Key Market Challenges & Risks of Acute Migraine Drugs

Table 60. Key Industry Trends of Acute Migraine Drugs

Table 61. Acute Migraine Drugs Raw Material

Table 62. Key Suppliers of Raw Materials

Table 63. Acute Migraine Drugs Distributors List

Table 64. Acute Migraine Drugs Customer List

Table 65. Global Acute Migraine Drugs Sales Forecast by Region (2025-2030) & (K Unit)

Table 66. Global Acute Migraine Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 67. Americas Acute Migraine Drugs Sales Forecast by Country (2025-2030) & (K Unit)

Table 68. Americas Acute Migraine Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 69. APAC Acute Migraine Drugs Sales Forecast by Region (2025-2030) & (K Unit)

Table 70. APAC Acute Migraine Drugs Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 71. Europe Acute Migraine Drugs Sales Forecast by Country (2025-2030) & (K Unit)

Table 72. Europe Acute Migraine Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 73. Middle East & Africa Acute Migraine Drugs Sales Forecast by Country (2025-2030) & (K Unit)

Table 74. Middle East & Africa Acute Migraine Drugs Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 75. Global Acute Migraine Drugs Sales Forecast by Type (2025-2030) & (K Unit)

Table 76. Global Acute Migraine Drugs Revenue Forecast by Type (2025-2030) & (\$ Millions)

Table 77. Global Acute Migraine Drugs Sales Forecast by Application (2025-2030) & (K Unit)

Table 78. Global Acute Migraine Drugs Revenue Forecast by Application (2025-2030) &

(\$ Millions)

Table 79. GSK Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 80. GSK Acute Migraine Drugs Product Portfolios and Specifications

Table 81. GSK Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 82. GSK Main Business

Table 83. GSK Latest Developments

Table 84. Teva Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 85. Teva Acute Migraine Drugs Product Portfolios and Specifications

Table 86. Teva Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 87. Teva Main Business

Table 88. Teva Latest Developments

Table 89. Pfizer Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 90. Pfizer Acute Migraine Drugs Product Portfolios and Specifications

Table 91. Pfizer Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 92. Pfizer Main Business

Table 93. Pfizer Latest Developments

Table 94. Novartis Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 95. Novartis Acute Migraine Drugs Product Portfolios and Specifications

Table 96. Novartis Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 97. Novartis Main Business

Table 98. Novartis Latest Developments

Table 99. Sun Pharma Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 100. Sun Pharma Acute Migraine Drugs Product Portfolios and Specifications

Table 101. Sun Pharma Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 102. Sun Pharma Main Business

Table 103. Sun Pharma Latest Developments

Table 104. Grunenthal Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 105. Grunenthal Acute Migraine Drugs Product Portfolios and Specifications

Table 106. Grunenthal Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 107. Grunenthal Main Business

Table 108. Grunenthal Latest Developments

Table 109. Endo Pharmaceuticals Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 110. Endo Pharmaceuticals Acute Migraine Drugs Product Portfolios and Specifications

Table 111. Endo Pharmaceuticals Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 112. Endo Pharmaceuticals Main Business

Table 113. Endo Pharmaceuticals Latest Developments

Table 114. Merck Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 115. Merck Acute Migraine Drugs Product Portfolios and Specifications

Table 116. Merck Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 117. Merck Main Business

Table 118. Merck Latest Developments

Table 119. J & J Basic Information, Acute Migraine Drugs Manufacturing Base, Sales Area and Its Competitors

Table 120. J & J Acute Migraine Drugs Product Portfolios and Specifications

Table 121. J & J Acute Migraine Drugs Sales (K Unit), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2019-2024)

Table 122. J & J Main Business

Table 123. J & J Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Acute Migraine Drugs
- Figure 2. Acute Migraine Drugs Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Acute Migraine Drugs Sales Growth Rate 2019-2030 (K Unit)
- Figure 7. Global Acute Migraine Drugs Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Acute Migraine Drugs Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of Triptans
- Figure 10. Product Picture of NSAIDs
- Figure 11. Product Picture of Others
- Figure 12. Global Acute Migraine Drugs Sales Market Share by Type in 2023
- Figure 13. Global Acute Migraine Drugs Revenue Market Share by Type (2019-2024)
- Figure 14. Acute Migraine Drugs Consumed in Hospital Pharmacies
- Figure 15. Global Acute Migraine Drugs Market: Hospital Pharmacies (2019-2024) & (K Unit)
- Figure 16. Acute Migraine Drugs Consumed in Drug Stores
- Figure 17. Global Acute Migraine Drugs Market: Drug Stores (2019-2024) & (K Unit)
- Figure 18. Global Acute Migraine Drugs Sales Market Share by Application (2023)
- Figure 19. Global Acute Migraine Drugs Revenue Market Share by Application in 2023
- Figure 20. Acute Migraine Drugs Sales Market by Company in 2023 (K Unit)
- Figure 21. Global Acute Migraine Drugs Sales Market Share by Company in 2023
- Figure 22. Acute Migraine Drugs Revenue Market by Company in 2023 (\$ Million)
- Figure 23. Global Acute Migraine Drugs Revenue Market Share by Company in 2023
- Figure 24. Global Acute Migraine Drugs Sales Market Share by Geographic Region (2019-2024)
- Figure 25. Global Acute Migraine Drugs Revenue Market Share by Geographic Region in 2023
- Figure 26. Americas Acute Migraine Drugs Sales 2019-2024 (K Unit)
- Figure 27. Americas Acute Migraine Drugs Revenue 2019-2024 (\$ Millions)
- Figure 28. APAC Acute Migraine Drugs Sales 2019-2024 (K Unit)
- Figure 29. APAC Acute Migraine Drugs Revenue 2019-2024 (\$ Millions)
- Figure 30. Europe Acute Migraine Drugs Sales 2019-2024 (K Unit)
- Figure 31. Europe Acute Migraine Drugs Revenue 2019-2024 (\$ Millions)
- Figure 32. Middle East & Africa Acute Migraine Drugs Sales 2019-2024 (K Unit)

- Figure 33. Middle East & Africa Acute Migraine Drugs Revenue 2019-2024 (\$ Millions)
- Figure 34. Americas Acute Migraine Drugs Sales Market Share by Country in 2023
- Figure 35. Americas Acute Migraine Drugs Revenue Market Share by Country in 2023
- Figure 36. Americas Acute Migraine Drugs Sales Market Share by Type (2019-2024)
- Figure 37. Americas Acute Migraine Drugs Sales Market Share by Application (2019-2024)
- Figure 38. United States Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 39. Canada Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 40. Mexico Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 41. Brazil Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 42. APAC Acute Migraine Drugs Sales Market Share by Region in 2023
- Figure 43. APAC Acute Migraine Drugs Revenue Market Share by Regions in 2023
- Figure 44. APAC Acute Migraine Drugs Sales Market Share by Type (2019-2024)
- Figure 45. APAC Acute Migraine Drugs Sales Market Share by Application (2019-2024)
- Figure 46. China Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 47. Japan Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 48. South Korea Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 49. Southeast Asia Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 50. India Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 51. Australia Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 52. China Taiwan Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 53. Europe Acute Migraine Drugs Sales Market Share by Country in 2023
- Figure 54. Europe Acute Migraine Drugs Revenue Market Share by Country in 2023
- Figure 55. Europe Acute Migraine Drugs Sales Market Share by Type (2019-2024)
- Figure 56. Europe Acute Migraine Drugs Sales Market Share by Application (2019-2024)
- Figure 57. Germany Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 58. France Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 59. UK Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 60. Italy Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 61. Russia Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)
- Figure 62. Middle East & Africa Acute Migraine Drugs Sales Market Share by Country in 2023
- Figure 63. Middle East & Africa Acute Migraine Drugs Revenue Market Share by Country in 2023
- Figure 64. Middle East & Africa Acute Migraine Drugs Sales Market Share by Type (2019-2024)
- Figure 65. Middle East & Africa Acute Migraine Drugs Sales Market Share by

Application (2019-2024)

Figure 66. Egypt Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 67. South Africa Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 68. Israel Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 69. Turkey Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 70. GCC Country Acute Migraine Drugs Revenue Growth 2019-2024 (\$ Millions)

Figure 71. Manufacturing Cost Structure Analysis of Acute Migraine Drugs in 2023

Figure 72. Manufacturing Process Analysis of Acute Migraine Drugs

Figure 73. Industry Chain Structure of Acute Migraine Drugs

Figure 74. Channels of Distribution

Figure 75. Global Acute Migraine Drugs Sales Market Forecast by Region (2025-2030)

Figure 76. Global Acute Migraine Drugs Revenue Market Share Forecast by Region (2025-2030)

Figure 77. Global Acute Migraine Drugs Sales Market Share Forecast by Type (2025-2030)

Figure 78. Global Acute Migraine Drugs Revenue Market Share Forecast by Type (2025-2030)

Figure 79. Global Acute Migraine Drugs Sales Market Share Forecast by Application (2025-2030)

Figure 80. Global Acute Migraine Drugs Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Acute Migraine Drugs Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GA4B2935FD7EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GA4B2935FD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970